DeJohn Joseph A. 4/A
4/A · ENDOLOGIX INC /DE/ · Filed Oct 2, 2012
Insider Transaction Report
Form 4/AAmended
DeJohn Joseph A.
Vice President - Sales
Transactions
- Award
Common Stock
2012-09-09$12.62/sh+28,944$365,273→ 112,626 total
Footnotes (7)
- [F1]40% vesting to occur upon achievement of U.S. revenue target for a quarter.
- [F2]40% vesting to occur upon consecutive growth targets over several quarters.
- [F3]5% vesting to occur upon the achievement of Nellix device revenue target for a month.
- [F4]5% vesting to occur upon U.S. regulatory approval of Nellix device.
- [F5]5% vesting to occur upon U.S. regulatory approval of Ventana device.
- [F6]5% vesting to occur upon U.S.regulatory approval of a second-generation AFX device.
- [F7]100% cliff vesting to occur 9/9/2016 in the event milestones are not achieved.